Results 11 to 20 of about 26,651 (230)

Adeno‐associated virus serotype 2 capsid variants for improved liver‐directed gene therapy

Hepatology, EarlyView., 2022
Abstract Background and Aims Current liver‐directed gene therapies look for adeno‐associated virus (AAV) vectors with improved efficacy. With this background, capsid engineering is explored. Whereas shuffled capsid library screenings have resulted in potent liver targeting variants with one first vector in human clinical trials, modifying natural ...
Nadja Meumann, Marti Cabanes‐Creus, Moritz Ertelt, Renina Gale Navarro, Julie Lucifora, Qinggong Yuan, Karin Nien‐Huber, Ahmed Abdelrahman, Xuan‐Khang Vu, Liang Zhang, Ann‐Christin Franke, Christian Schmithals, Albrecht Piiper, Annabelle Vogt, Maria Gonzalez‐Carmona, Jochen T. Frueh, Evelyn Ullrich, Philip Meuleman, Steven R. Talbot, Margarete Odenthal, Michael Ott, Erhard Seifried, Clara T. Schoeder, Joachim Schwäble, Leszek Lisowski, Hildegard Büning   +25 more
wiley   +1 more source

Niacin restriction with NAMPT-inhibition is synthetic lethal to neuroendocrine carcinoma

Nature Communications, 2023
Nicotinamide phosphoribosyltransferase (NAMPT) plays a major role in NAD biosynthesis in many cancers and is an attractive potential cancer target. However, factors dictating therapeutic efficacy of NAMPT inhibitors (NAMPTi) are unclear.
Miyuki Nomura, Mai Ohuchi, Yoshimi Sakamoto, Kei Kudo, Keisuke Yaku, Tomoyoshi Soga, Yuki Sugiura, Mami Morita, Kayoko Hayashi, Shuko Miyahara, Taku Sato, Yoji Yamashita, Shigemi Ito, Naohiko Kikuchi, Ikuro Sato, Rintaro Saito, Nobuo Yaegashi, Tatsuro Fukuhara, Hidekazu Yamada, Hiroshi Shima, Keiichi I. Nakayama, Atsushi Hirao, Kenta Kawasaki, Yoichi Arai, Shusuke Akamatsu, Sei-ichi Tanuma, Toshiro Sato, Takashi Nakagawa, Nobuhiro Tanuma   +28 more
doaj   +1 more source

Nicotinamide Phosphoribosyltransferase in Human Diseases [PDF]

Journal of Bioanalysis & Biomedicine, 2011
Nicotinamide phosphoribosyltransferase (NAMPT) was first reported as a pre-B-cell colony enhancing factor in 1994 with little notice, but it has received increasing attention in recent years due to accumulating evidence indicating that NAMPT is a pleiotropic protein such as a growth factor, a cytokine, an enzyme and a visfatin.
Shui Qing Ye, Li Qin Zhang, Daniel P. Heruth   +2 more
openaire   +4 more sources

Recent Advances in NAMPT Inhibitors: A Novel Immunotherapic Strategy

Frontiers in Pharmacology, 2020
Nicotinamide adenine dinucleotide (NAD) is a cofactor of many enzymatic reactions as well as being a substrate for a number of NAD-consuming enzymes (e.g., PARPS, sirtuins, etc).
Ubaldina Galli, Giorgia Colombo, Cristina Travelli, Gian Cesare Tron, Armando A. Genazzani, Ambra A. Grolla   +5 more
doaj   +1 more source

Identification of NAPRT Inhibitors with Anti-Cancer Properties by In Silico Drug Discovery

Pharmaceuticals, 2022
Depriving cancer cells of sufficient NAD levels, mainly through interfering with their NAD-producing capacity, has been conceived as a promising anti-cancer strategy. Numerous inhibitors of the NAD-producing enzyme, nicotinamide phosphoribosyltransferase
Moustafa S. Ghanem, Irene Caffa, Alberto Del Rio, Jorge Franco, Marco Daniele Parenti, Fiammetta Monacelli, Michele Cea, Amr Khalifa, Aimable Nahimana, Michel A. Duchosal, Silvia Ravera, Nadia Bertola, Santina Bruzzone, Alessio Nencioni, Francesco Piacente   +14 more
doaj   +1 more source

Crystallization of human nicotinamide phosphoribosyltransferase [PDF]

Acta Crystallographica Section F Structural Biology and Crystallization Communications, 2007
In the NAD biosynthetic pathway, nicotinamide phosphoribosyltransferase (NMPRTase; EC 2.4.2.12) plays an important role in catalyzing the synthesis of nicotinamide mononucleotide from nicotinamide and 5'-phosphoribosyl-1'-pyrophosphate. Because the diffraction pattern of the initially obtained crystals was not suitable for structure analysis, the ...
Ryo Takahashi, Yuji Kobayashi, Yuji Kobayashi, Tadayasu Ohkubo, Shota Nakamura, Takuya Yoshida   +5 more
openaire   +3 more sources

The role of sirtuin 2 activation by nicotinamide phosphoribosyltransferase in the aberrant proliferation and survival of myeloid leukemia cells

Haematologica, 2012
Background Inhibitors of nicotinamide phosphoribosyltransferase have recently been validated as therapeutic targets in leukemia, but the mechanism of leukemogenic transformation downstream of this enzyme is unclear.Design and Methods Here, we evaluated ...
Lan Dan, Olga Klimenkova, Maxim Klimiankou, Jan-Henning Klusman, Marry M. van den Heuvel-Eibrink, Dirk Reinhardt, Karl Welte, Julia Skokowa   +7 more
doaj   +1 more source

SIRT1 selectively exerts the metabolic protective effects of hepatocyte nicotinamide phosphoribosyltransferase

Nature Communications, 2022
NAD + metabolism is potential target to treat metabolic disorders, in part due to the effects of the NAD + dependent enzyme Sirt1. Here the authors report that hepatic nicotinamide phosphoribosyltransferase, a rate-limiting step in the NAD + salvage ...
Cassandra B. Higgins, Allyson L. Mayer, Yiming Zhang, Michael Franczyk, Samuel Ballentine, Jun Yoshino, Brian J. DeBosch   +6 more
doaj   +1 more source

NAMPT (nicotinamide phosphoribosyltransferase) [PDF]

Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2012
Review on NAMPT (nicotinamide phosphoribosyltransferase), with data on DNA, on the protein encoded, and where the gene is implicated.
Koumaki, V, Dalamaga, M
openaire   +3 more sources

PRTFDC1 is a genetic modifier of HPRT-deficiency in the mouse. [PDF]

PLoS ONE, 2011
Lesch-Nyhan disease (LND) is a severe X-linked neurological disorder caused by a deficiency of hypoxanthine phosphoribosyltransferase (HPRT). In contrast, HPRT-deficiency in the mouse does not result in the profound phenotypes such as self-injurious ...
Alaine C Keebaugh, Heather A Mitchell, Meriem Gaval-Cruz, Kimberly G Freeman, Gaylen L Edwards, David Weinshenker, James W Thomas   +6 more
doaj   +1 more source